

Our File No.: 20040873.ORI

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re App : Adrian Hill et al : February 23, 2005  
S.N. : 10/511,415 : Art Unit Unknown  
Filed : October 14, 2004  
For : METHODS OF TREATMENT AND DIAGNOSIS OF  
PATIENTS WITH HEPATITIS C INFECTION

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER RULE 1.56

Applicant(s) herein make available to the Patent and Trademark Office a copy of Form PTO-1449 which lists the following document(s), copies of which are enclosed. This Information Disclosure Statement is being filed in accordance with the following provision(s):

- 37 CFR 1.97(b)(1) Within three months of the filing date of the national application. No fee is required.
- 37 CFR 1.97(b)(2) Within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in the international application. No fee is required.
- 37 CFR 1.97(b)(3) Before the mailing date of a first Office Action on the merits. No fee is required.
- 37 CFR 1.97(c) After the periods specified in 37 CFR 1.97(b), but before the mailing date of either: (1) a



final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.

[ ] The undersigned hereby certifies that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; or

[ ] The undersigned hereby certifies that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; or

[ ] Enclosed is a check in the amount of \$200.00 for the fee set forth in 37 CFR § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. 1.17, or credit any overpayment, to Deposit Account No. 08-1265. Two copies of this sheet are enclosed.

[ ] 37 CFR 1.97(d) After the mailing date of either (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first, but before payment of the issue fee.

[ ] Applicant(s) hereby petition the Commissioner of Patents and Trademarks to consider this information disclosure statement. Enclosed is a check in the amount of \$130.00 for the petition fee set forth in § 1.17(i)(1). The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. 1.17, or credit any overpayment, to Deposit Account No. 08-1265. Two copies of this sheet are enclosed.

The Examiner is requested to consider carefully the complete text of these documents in connection with the examination of the



above-identified application in accordance with 37 CFR 1.104(a). It is requested that the documents listed on the attached Form PTO-1449 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. 1302.12), and that the Examiner initial and return a copy of the form to evidence consideration of the documents.

Dated: February 23, 2005. Respectfully submitted,

NIKOLAI & MERSEREAU, P.A.


C. G. Mersereau  
Attorney for Applicant(s)  
Registration No. 26,205  
900 Second Avenue South  
Suite 820  
Minneapolis, MN 55402  
Phone: 612-339-7461

#### CERTIFICATE OF MAILING

I hereby certify that the foregoing Information Disclosure Statement Under Rule 1.56, Form PTO-1449 and a copy of each cited reference to be filed in connection with application Serial No. 10/511,415 of inventors, Adrian Hill et al, filed October 14, 2004, for "METHODS OF TREATMENT AND DIAGNOSIS OF PATIENTS WITH HEPATITIS C INFECTION" are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 23, 2005.

Barbara L. Davis  
Secretary to C. G. Mersereau

Date of Signature: February 23, 2005



PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Document Number 20040873.0RI	Application Number 10/511,415
	Applicant Adrian Hill et al	
	Filing Date October 14, 2004	Group Art Unit Unknown

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**


	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES   NO
	WO 02/090552	11/14/02	PCT			
	WO 02/06343	01/24/02	PCT			
	WO 02/081741	10/17/02	PCT			
	WO 02/081511	10/17/02	PCT			

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Papers, Etc.)

	Carreno et al, CYTOKINE, <i>Randomized Controlled Trial of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor for the Treatment of Chronic Hepatitis C</i> , Vol. 12, No. 2, February 2000, pp. 165-170
	Rusch et al, METHODS IN ENZYMOLOGY, <i>Monitoring Activation of Ribonuclease L by 2',5'-Oligoadenylates Using Purified Recombinant Enzyme and Intact Malignant Glioma Cells</i> , Vol. 342, 2001, pp. 10-20
	Sarkar et al, METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, <i>Production, Purification and Characterization of Recombinant 2',5'-Oligoadenylate Synthetases</i> , Vol. 15, 1998, pp. 233-242
	Ichikawa et al, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, <i>Geranylgeranylacetone Induces Antiviral Gene Expression in Human Hepatoma Cells</i> , Vol. 26, 2001, pp. 933-939
	Alter et al, HEPATOLOGY, <i>Hepatitis C in Asymptomatic Blood Donors</i> , Vol. 26, 1997, pp. 29S-33S
	Callan et al, J. EXP. Med., <i>Direct Visualization of Antigen-specific CD8<sup>+</sup> T Cells during the Primary Immune Response to Epstein-Barr Virus in Vivo</i> , Vol. 187, 1998, pp. 1395-1402
	Chieux et al, JOURNAL OF VIROLOGICAL METHODS, <i>The MxA Protein Levels in Whole Blood Lysates of Patients with Various Viral Infections</i> , Vol. 70, 1998, pp. 183-191

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



FORM PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Document Number 20040873.ORI	Application Number 10/511,415
	Applicant Adrian Hill et al	
	Filing Date October 14, 2004	Group Art Unit Unknown

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**


	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Papers, Etc.)

	Crowe et al, GASTROENTEROLOGY, <i>Presentation of Hepatitis C in a Unique Uniform Cohort 17 Years from Inoculation</i> , Vol. 108, 1995, pp. A1054
	Der et al, PROC. NATL. ACAD. SCI USA, <i>Identification of Genes Differentially Regulated by Interferon <math>\alpha</math>, <math>\beta</math>, or <math>\gamma</math> Using Oligonucleotide Arrays</i> , Vol. 95, 1998, pp. 15623-15628
	Donohue et al, BRITISH JOURNAL OF HAEMATOLOGY, <i>Alpha Interferon in the Treatment of Chronic Hepatitis C Infection in Thalassaemia Major</i> , Vol. 83, 1993, pp. 491-497
	Enomoto et al, JOURNAL OF CLINICAL INVESTIGATION, <i>Comparison of Full-length Sequences of Interferon-Sensitive and Resistant Hepatitis C Virus 1b</i> , Vol. 96, July 1995, pp. 224-230
	Feng et al, PROC. NATL. ACAD. SCI USA, <i>Identification of Double-stranded RNA-binding Domains in the Interferon-induced Double-stranded RNA-activated p68 Kinase</i> , Vol. 89, June 1992, pp. 5447-5551
	Gale et al, VIROLOGY, <i>Evidence that Hepatitis C Virus Resistance to Interferon is Mediated through Repression of the PKR Protein Kinase by the Nonstructural 5A Protein</i> , Vol. 230, 1997, pp. 217-227
	Gallimore et al, JOURNAL OF EXP. MEDICINE, <i>Induction and Exhaustion of Lymphocytic Choriomeningitis Virus-specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric Major Histocompatibility Complex Class i-Peptide Complexes</i> , Vol. 187, 1998, pp. 1383-1393
	Genbank Accession Number M11810

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



Form P-1449

Document Number  
20040873.ORI

Application Number  
10/511,415

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Applicant  
Adrian Hill et al

Filing Date  
October 14, 2004

Group Art Unit  
Unknown

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
------------------	-----------------	------	------	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS


	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
--	-----------------	------	---------	-------	----------	--

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

	Goto et al, CLINICAL CANCER RESEARCH, A Novel Single-Nucleotide Polymorphism in the 3'-Untranslated Region of the Human Dihydrofolate Reductase Gene with Enhanced Expression, Vol. 7, July 2001, pp. 1952-1956
	Gribaudo et al, JOURNAL OF VIROLOGY, Interferon Action: Binding of viral RNA to the 40-Kilodalton 2'-5'-Oligoadenylate Synthetase in Interferon-Treated HeLa Cells Infected with Encephalomyocarditis Virus, Vol. 65, No. 4, April 1991, pp. 1748-1757
	Hoofnagle et al, NEW ENGLAND JOURNAL OF MEDICINE, Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha Interferon, Vol. 315, No. 25, 1986, pp. 1575-1578
	Imbert-Bismut et al, LANCET, Biochemical Markers of Liver Fibrosis in Patients with Hepatitis C Virus Infection: a Prospective Study, Vol. 357, April 7, 2001, pp. 1069-1075
	Kenny et al, NEW ENGLAND JOURNAL OF MEDICINE, Clinical Outcomes After Hepatitis C Infection from Contaminated Anti-D Immune Globulin, Vol. 340, April 22, 1999, pp. 1228-1233
	Mannis et al, LANCET, Peginterferon Alfa-2b Plus Ribavirin Compared with Interferon Alfa-2b Plus Ribavirin for Initial Treatment of Chronic Hepatitis C: a Randomised Trial, Vol. 358, September 22, 2001, pp. 958-965
	Murashima et al, JOURNAL OF MEDICAL VIROLOGY, Effect of Interferon Treatment on Serum 2',5'-Oligoadenylate Synthetase Levels in Hepatitis C-Infected Patients, Vol. 62, 2000, pp. 185-190
	Rosenberg et al, BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER MEETING, Serum Markers Predict Liver Fibrosis, 2001, Book of Abstracts, p. 23
	Sharara et al, ANNALS OF INTERNAL MEDICINE, Hepatitis C, Vol. 125, Issue 8, October 15, 1996, pp. 658-668

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



Form 10-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Document Number 20040873.ORI	Application Number 10/511,415
	Applicant Adrian Hill et al	
	Filing Date October 14, 2004	Group Art Unit Unknown

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**


	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Papers, Etc.)

	Thomas et al, JOURNAL OF HEPATOLOGY, Possible Mechanisms of Action and Reasons for Failure of Antiviral Therapy in Chronic Hepatitis C, Vol. 31, Suppl. 1, 1999, pp. 152-159
	Tong et al, NEW ENGLAND JOURNAL OF MEDICINE, Clinical Outcomes After Transfusion-associated Hepatitis C, Vol. 332, No. 22, 1995, pp. 1463-1466
	Urosevic et al, JOURNAL OF GENERAL VIROLOGY, Development and Characterization of New Flavivirus-Resistant Mouse Strains Bearing <i>Flv<sup>r</sup></i> -like and <i>Flv<sup>mr</sup></i> Alleles from Wild or Wild-derived Mice, Vol. 80, 1999, pp. 897-906
	Yan et al, PROC. NATL. ACAD. SCI U.S.A., Signal Transduction Pathways in the Induction of 2',5'-Oligoadenylate Synthetase Gene Expression by Interferon $\alpha/\beta$ , Vol. 86, No. 7, April 1, 1989, pp. 2243-2247
	Yu et al, HEPATOLOGY, Intrahepatic mRNA Expression of Interferon-Inducible Antiviral Genes in Liver Diseases: dsRNA-Dependent Protein Kinase Overexpression and RNase L Inhibitor Suppression in Chronic Hepatitis C, Vol. 32, 2000, pp. 1089-1095
	Zhou et al, EMBO JOURNAL, Interferon Action and Apoptosis are Defective in Mice Devoid of 2',5'-Oligoadenylate-Dependent RNase L, Vol. 16, No. 21, 1997, pp. 6355-6363
	Guenet et al, Printout from a website concerning "DNA Molecules Containing 2',5'-Oligoadenylate Synthetase (OAS) Family Genes and Their Use in Drug Screening and Development of New Therapies Against Flaviviridae Infections", January 20, 2002
	Mashimo et al, PROC. NATL. ACAD. SCI. USA, A Nonsense Mutation in the Gene Encoding 2'-5'-Oligoadenylate Synthetase/L1 Isoform is Associated With West Nile Virus Susceptibility in Laboratory Mice, Vol. 99, No. 17, August 20, 2002, pp. 11311-11316

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



Form STO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)	Document Number 20040873.ORI	Application Number 10/511,415
	Applicant Adrian Hill et al	
	Filing Date October 14, 2004	Group Art Unit Unknown

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES <input type="checkbox"/> NO <input type="checkbox"/>
	2,823,218	04/04/01	France			
	2,823,224	04/04/01	France			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)**

	Wilson et al, JOURNAL OF BIOLOGICAL CHEMISTRY, <i>Amplification and Molecular Cloning of the IMP Dehydrogenase Gene of Leishmania Donovani</i> , Vol. 266, No. 3, January 25, 1991, pp. 1665-1671
	Malnick et al, ANNALS OF PHARMACOTHERAPY, <i>Treatment of Chronic Hepatitis C Virus Infection</i> , Vol. 34, October 2000, pp. 1156-1164

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.